Moreover, treatment switch from agalsidase alfa to agalsidase beta has been shown to attenuate estimated glomerular filtration rate (eGFR) decline [11–13], which confirms the dose-dependent effect including a slowdown in renal disease progression, with agalsidase alfa and agalsidase beta being the two widely used forms. The gene discussed is GLA; the disease is kidney disorder.